Trethera Corporation
Publicly observedSherman Oaks, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Sherman Oaks | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Trethera Corporation | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | QB66ZMAUF5P7 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant8 Sept 2025Publicly observed
NIH SBIR/STTR award: Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through murine studies to enable further clinical advancement in non-small-cell lung cancer
USD 406,500.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant18 Aug 2025Publicly observed
NIH SBIR/STTR award: Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through combinatorial murine studies to enable further clinical advancement in prostate tumors
USD 1,150,000.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant18 Aug 2025Publicly observed
NIH SBIR/STTR award: Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through combinatorial murine studies to enable further clinical advancement in prostate tumors
USD 1,150,000.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant7 Aug 2025Publicly observed
NIH SBIR/STTR award: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus
USD 994,978.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant7 Aug 2025Publicly observed
NIH SBIR/STTR award: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus
USD 994,978.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant2 Jul 2024Publicly observed
NIH SBIR/STTR award: Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM)
USD 1,000,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant18 Sept 2023Publicly observed
NIH SBIR/STTR award: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease
USD 897,265.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant18 Sept 2023Publicly observed
NIH SBIR/STTR award: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease
USD 905,290.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant30 Sept 2022Publicly observed
NIH SBIR/STTR award: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis
USD 622,448.00 · National Eye Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.